Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1

Hypertension in Pregnancy

Volumn 33, Issue 2, 2014, Pages 250-259

  Bdolah, Yuval ^a   Elchalal, Uriel ^a   Natanson Yaron, Shira ^a   Yechiam, Hadas ^a   Bdolah Abram, Tali ^a   Greenfield, Caryn ^a   Goldman Wohl, Debra ^a   Milwidsky, Ariel ^a   Rana, Sarosh ^b   Karumanchi, S Ananth ^b   Yagel, Simcha ^a   Hochner Celnikier, Drorith ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Nulliparity; Preeclampsia; Primigravity; SFlt1

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BIRTH WEIGHT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS WEIGHT; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; MULTIPARA; NULLIPARA; PREECLAMPSIA; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THIRD TRIMESTER PREGNANCY; BLOOD; COMPARATIVE STUDY; PARITY; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY; YOUNG ADULT;

ADULT; FEMALE; HUMANS; PARITY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, THIRD; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84898851835     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2013.858745     Document Type: Article

References (38)

1. Luo ZC, An N, Xu HR, et al. The effects and mechanisms of primiparity on the risk of pre-eclampsia: a systematic review. Paediatr Perinat Epidemiol 2007;21:36-45
2. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565
3. Deis S, Rouzier R, Kayem G, et al. Development of a nomogram to predict occurrence of preeclampsia. Eur J Obstet Gynecol Reprod Biol 2007;137:146-51
4. Dildy 3rd GA, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007;31:135-41
5. Badria LF, Amarin ZO. Pre-eclampsia: is it a different disease in primiparous and multiparous women? Arch Gynecol Obstet 2005;273:26-31
6. Dukler D, Porath A, Bashiri A, et al. Remote prognosis of primiparous women with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001;96:69-74
7. Dekker GA, Robillard PY, Hulsey TC. Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv 1998;53:377-82
8. Mekori YA, Becker M, Moalem I, et al. Immunological features of preeclampsia: increased frequency of antilymphocyte antibodies, but not of immune complexes. Isr J Med Sci 1981;17:1051-5
9. Barden AE, Beilin LJ, Ritchie J, et al. Is proteinuric pre-eclampsia a different disease in primigravida and multigravida? Clin Sci (Lond) 1999;97:475-83
10. Wolf M, Sandler L, Jimenez-Kimble R, et al. Insulin resistance but not inflammation is associated with gestational hypertension. Hypertension 2002;40:886-91
11. Lachmeijer AM, Dekker GA, Pals G, et al. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 2002;105:94-113
12. Mijal RS, Holzman CB, Rana S, et al. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244 e1-12
13. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58
14. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123:2856-69
15. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63
16. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-8
17. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-51
18. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7; discussion 1547-50
19. Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50:1702-3
20. Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478-87
21. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77-85
22. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005
23. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-19
24. Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 2006;194:239-45
25. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198:428 e1-6
26. Koga K, Osuga Y, Tajima T, et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010;94:305-8
27. Kanter D, Lindheimer MD, Wang E, et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010;202:184 e1-5
28. Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198:200 e1-7
29. Mijal RS, Holzman CB, Rana S, et al. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244 e1-12
30. Faupel-Badger JM, Staff AC, Thadhani R, et al. Maternal angiogenic profile in pregnancies that remain normotensive. Eur J Obstet Gynecol Reprod Biol 2011; 158:189-93
31. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161 e1-161 e11
32. Parazzini F, Bortolus R, Chatenoud L, et al. Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group. Epidemiology 1996;7:306-8
33. Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG 2000;107:75-83
34. Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT- 1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005;193: 16-22
35. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-andegg" question. Endocrinology 2004;145:4835-7
36. Odegard RA, Vatten LJ, Nilsen ST, et al. Risk factors and clinical manifestations of pre-eclampsia. BJOG 2000;107:1410-16
37. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003-10
38. Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002;187: 1013-18.